Meet Our Kitchen Table Society Awardees
Celebrate PHA’s 2026 Kitchen Table Society Award winners, honored for their support, trust and commitment to PHA’s mission.
Events | News
In the News
Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.
Recent news
Dislaying 1 — 6 of 380
-
-
PHA 2026: Connecting the Community from Across Town and Around the GlobePHA 2026 International PH Conference draws 1,000 global attendees to learn, connect, and celebrate PH advancements—see highlights and photos.
Events
-
9 Volunteers Who Go the Extra MilePHA honored nine dedicated members of the PH community during a ceremony at the PHA 2026 International PH Conference and Scientific Sessions in Dallas.
Events | News
-
How PHA Conferences Benefit the PH CommunityPHA 2026 delivers support, information, and hope—advancing care to enhance and extend lives affected by pulmonary hypertension, even beyond the conference.
News
-
Speak Out for Oxygen AccessUrge Congress to support the SOAR Act by joining our June advocacy challenge.
Get involved
-
New in Pathlight: Inspiring Patient Stories and MoreSawanda Cornett shares her 22-year PH journey in the latest issue of Pathlight, PHA's member magazine.
News
PH in the News
Ralinepag shows delayed disease progression in PAH study
Ralinepag met a primary goal to delay disease progression in a Phase 3 study, United Therapeutics announced. The study met several secondary goals, including six-minute walk distance.
Read morePulmovant completes Phase 2 study enrollment for PH-ILD drug
Pulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD. Mosliciguat helps widen blood vessels and could have anti-inflammatory and anti-fibrotic properties.
Read moreGossamer announces topline results from Phase 3 seralutinib study
Gossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24, according to its news release. An unexpectedly large improvement in walk distance in the placebo group appeared in part to influence the outcome, Gossamer says. The company noted encouraging findings in key secondary goals, including reductions in NT-proBNP, improvements in clinical status and lower risk scores. The study also showed meaningful treatment effects in patients with intermediate and high-risk PH, Gossamer explains in a document for patients (pdf).
Read more